Wealth Enhancement Advisory Services
ADMA icon

Wealth Enhancement Advisory Services’s ADMA Biologics ADMA Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$438K Buy
63,254
+32,507
+106% +$296K ﹤0.01% 2816
2026
Q1 		$95.7K Buy
30,747
+24,684
+407% +$390K ﹤0.01% 3325
2025
Q4 		$117K Buy
6,063
+634
+12% +$10.7K ﹤0.01% 3402
2025
Q3 		$76K Buy
+5,429
New +$93.1K ﹤0.01% 3373

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Wealth Enhancement Advisory Services's ADMA Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its ADMA Biologics (ADMA) stake by 106% in Q2 2026, buying an estimated $296K and bringing the position to 63,254 shares worth $438K. The position accounts for ﹤0.01% of the portfolio, ranked #2816.

Wealth Enhancement Advisory Services first reported a position in ADMA in Q3 2025 and has held it in 4 quarters since. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Wealth Enhancement Advisory Services held 63,254 shares of ADMA Biologics worth $438K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 32,507 ADMA Biologics shares in Q2 2026, an estimated $296K.
  • ADMA Biologics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2816 holding.
  • Wealth Enhancement Advisory Services first reported a position in ADMA Biologics in Q3 2025 and has held it in 4 quarters since.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.